Patents

Intellectual Property

Our Patent Portfolio

Country Application # ALPHA-1062 Technologies Anticipated Expiration Date
CA / CN / JP 2,721,007 / ZL200880128608.5 / 5504253 DERIVATIVES OF GALANTAMINE AS PRO-DRUGS FOR THE TREATMENT OF HUMAN BRAIN DISEASES 2028+
US US 9,763,953 / 10,265,325 CHOLINERGIC ENHANCERS WITH IMPROVED BLOOD-BRAIN BARRIER PERMEABILITY FOR THE TREATMENT OF DISEASES ACCOMPANIED BY COGNITIVE IMPAIRMENT 2026+
EP 2 137 192 DERIVATIVES OF GALANTAMINE AS PRO-DRUGS FOR THE TREATMENT OF HUMAN BRAIN DISEASES 2028+
EP / CA / AU / JP/ JP / JP 2877165 / 2878135 2013294917 / 6272857 / 6574002 / 2019-148915 ENHANCED BRAIN BIOAVAILABILITY OF GALANTAMINE BY SELECTED FORMULATIONS AND TRANSMUCOSAL ADMINISTRATION OF LIPOPHILIC PRODRUGS 2033
CN / HK / IN / US 2018101403258 / 19100111.3 / 201918046982/ 16/287,413 ENHANCED BRAIN BIOAVAILABILITY OF GALANTAMINE BY SELECTED FORMULATIONS AND TRANSMUCOSAL ADMINISTRATION OF LIPOPHILIC PRODRUGS 2033
EP Pending SELF-PRESERVING COMPOSITIONS AND MULTI-USE DISPENSERS FOR ADMINISTERING ALPHA-1062 2040
EP 21152317.0 Gluconate Polymorphs / API Manufacturing / Enteric Coated Tablet Synthesis / Sub-lingual Tablet Synthesis 2041
Country Application # ALPHA-0600 Series Anticipated Expiration Date
CA / CN / IN Pending / CN102006882 / 280570 PROGRANULIN FOR USE IN TREATING PARKINSON’S DISEASE OR ALZHEIMER’S DISEASE 2029
US Pending TREATING NEURODEGENRATIVE DISEASE WITH PROGRANULIN 2028+
EP / EP 2 249 861 / 3 009 143 PROGRANULIN FOR USE IN TREATING PARKINSON’S DISEASE OR ALZHEIMER’S DISEASE 2029+
US / JP Pending / 6312436 METHOD FOR INCREASING NEPRILYSIN EXPRESSION AND ACTIVITY 2031
+ Potential Patent Term Adjustment (35 U.S.C. §154) and Patent Term Extension (35 U.S.C. §156) compensate patent applicants for USPTO / FDA -caused delays, adding up to as much as 5 years of patent life.